Dr. Laura Hix Glickman, PhD, Co-founder and CEO for Adjuvia Therapeutics, has over 30 years of academic and biotech experience developing vaccines, small molecules, enzyme-based therapeutics and nucleic acid delivery platforms to treat cancer, infectious disease, autoimmunity, mitochondrial dysfunction, and hemophilia. She has previously served as Founder, Executive, Board Member, Advisor and Scientific Lead for multiple public and private biotech companies: Actym Therapeutics (BIVF, Panacea Ventures, Illumina Ventures, JLO Ventures), Aduro Biotech (NASDAQ: ADRO), Catalyst Biosciences (NASDAQ: CBIO), Hawaii Biotech, Cardax Pharmaceuticals (NASDAQ:CDXI), Selva Therapeutics, Allos, OptiGenix, Immunitas Consulting, and is a Berkeley SkyDeck Key Advisor and Member of the Bio Selection Committee. In 2020, Dr. Glickman was named the #5 top-ranked female Series A Founder in the U.S. across all industries by Female Founders Fund, with an oversubscribed Series A of $34MM for Actym. Dr. Glickman has 21 issued patents and multiple pending applications, over 20 research publications, and multiple successful FDA IND applications. As an undergraduate at UC Berkeley, she double majored in Psychology and Molecular and Cell Biology, and is proud to be a contributor to UC Berkeley’s #1 global status for the number of venture-backed startups founded by undergraduate alumni. She earned her PhD in Cancer Immunology from Northwestern University’s Feinberg School of Medicine, where she was a Department of Defense Predoctoral Fellow. She was among the 30 top Northwestern graduate students selected to participate in the Kellogg Business School’s Management for Scientists and Engineers Program, where she earned a certificate MBA.